J. Scott Garland
CIK 1533228 · President and CEO · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
10
Total Filings
44
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OLMA | Director | — | $11.62 | — | $0 | 4 | 2026-06-23 |
| LBRX | Director | — | $34.94 | — | $0 | 2 | 2026-06-05 |
| Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Director | — | $21.53 | — | $0 | 7 | 2026-04-23 |
| IMRA | Director | — | $14.49 | — | $0 | 2 | 2026-02-17 |
| ALXO | Director | — | $1.99 | — | $0 | 5 | 2026-01-21 |
| Calithera Biosciences, Inc. (CALA) Delisted | Director | — | $0.00 | — | $0 | 3 | 2022-06-03 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | President and CEO | 1,173 | — | — | $0 | 6 | 2020-07-02 |
| KPTI | Director | — | $7.09 | — | $0 | 6 | 2019-06-07 |
| Relypsa Inc (RLYP) Delisted | SVP & Chief Commercial Officer | 16,042 | — | — | $0 | 6 | 2016-09-02 |
| EXEL | EVP & Chief Commerical Officer | — | $56.51 | — | $0 | 3 | 2013-09-19 |
Recent Filings · Page 2 of 5
44 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-23 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2024-06-18 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2024-05-28 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-10-17 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2023-06-26 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-22 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2022-11-29 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2022-06-23 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-03 | Calithera Biosciences, Inc. (CALA) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.